Evidence map›Paper›PMID 24872138›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2014

Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.

Max R OʼDonnell, Allison Wolf, Lise Werner, C Robert Horsburgh, Nesri Padayatchi

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05633056 (Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05633056 narecruitingnot on this mapstarted 2023, after this paper: background citation

Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa

TypeinterventionalSponsorColumbia UniversityRan2023 to 2029Enrolled360ConditionsMulti Drug Resistant Tuberculosis, HIV InfectionsArmsAdherence support intevention
3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Pathogenesis of Human Immunodeficiency Virus-Journal of clinical medicine · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Max R OʼDonnell*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban, South Africa.
Allison Wolf
Lise Werner
C Robert Horsburgh
Nesri Padayatchi

Funding

Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic AreaK23AI098479 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · 2012 to 2016
$669k
NIAID NIH HHS 5K23AI098479NIAID NIH HHS K23 AI098479
6 · The paper itself

Abstract

objectiveExtensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes.

methodsProspective cohort study of XDR-TB patients on treatment in KwaZulu-Natal, South Africa. Adherence to ARV and TB medications was assessed separately at baseline and monthly. Knowledge, attitudes, and beliefs were assessed at baseline. Optimal adherence was defined as self-report of taking all pills in the previous 7 days; missing any pills was defined as suboptimal adherence. Primary outcome was optimal adherence 6 months after initiation of XDR-TB treatment to TB medications, ARV, and both ("dual adherence").

resultsOne hundred four XDR-TB patients (79.8% HIV coinfected, 84.3% on ARV at enrollment) were enrolled and followed monthly (median 8 visits; interquartile range: 4-12). Six-month optimal adherence was higher for ARV (88.2%) than TB medications (67.7%) (P < 0.001). Low educational attainment, male gender, and year of enrollment were independently associated with dual suboptimal adherence. At baseline, participants indicated that XDR-TB was curable (76.0%), HIV and TB were linked (81.7%), and ARV improves TB outcomes (72.1%). Baseline knowledge, attitudes, and beliefs did not predict subsequent adherence.

conclusionsMedication adherence was significantly higher for ARV than for TB medications in this cohort. Short-course treatment regimens for drug-resistant TB with lower pill burden may increase adherence and improve outcomes in XDR-TB/HIV. Programmatic support for dual adherence is critical in the treatment of drug-resistant TB and HIV.

Indexed as

Medication AdherenceAdolescentAdultAnti-HIV AgentsAntitubercular AgentsCohort StudiesExtensively Drug-Resistant TuberculosisFemaleHIV-1HIV InfectionsHumansLogistic ModelsMaleMiddle AgedMycobacterium tuberculosisProspective StudiesAnti-HIV AgentsAntitubercular Agents

Identifiers

PMID24872138
PMCPMC4410008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.